| ¿µ¹® | neoplasm | ÇÑ±Û | ½Å»ý¹° |
|---|---|---|---|
| ¼³¸í | »õ·Î »ý±ä ¹°ÁúÀ̶ó´Â ¶æÀÌ´Ù. À̰ÍÀº ´Ù¸¥ ¸»·Î ¡°Á¾¾ç(tumor)¡±À̶ó°íµµ ÇÏ´Â µ¥, ½ÇÁ¦·Î À̵éÀÇ ¸íÈ®ÇÑ ¶æÀº ¼·Î ´Ù¸£´Ù. Á¾¾çÀ̶ó´Â ¸»Àº ¡°±× Å©±â°¡ 1cm°¡ ³Ñ´Â ÀÏÁ¾ÀÇ È¤¡±À» ¸»ÇÏ´Â °ÍÀ¸·Î ÇǺΰú¿¡¼´Â À̺¸´Ù ÀÛÀº ȤÀ» ±¸ÁøÀ̶ó°í ÇÏ¿© ±¸º°ÇÏ¿© ºÎ¸¥´Ù. ÇÏÁö¸¸, À̰ÍÀº ¶ÇÇÑ ÇǺλӸ¸ ¾Æ´Ï¶ó ½Åü³» ¾îµð¿¡¼µç »ý±æ ¼ö ÀÖÀ¸¹Ç·Î ¸ðµÎ ÅëĪÇÏ¿© Á¾¾çÀ̶ó°í ºÎ¸¥´Ù. ÀÌ¿¡ ºñÇØ ¡°½Å»ý¹°¡±Àº ½Åü³» ¾ø´ø °ÍÀÌ »õ·Î »ý°Ü³µ´Ù´Â ¶æÀ¸·Î ºÙÀÎ ¸»ÀÌ´Ù. ±×·¯³ª, ÀÌ µÑÀÇ °ü°è¸¦ ¸íÈ®È÷ ±ÔÁ¤ÁþÁö ¾Ê°í ÀÖÀ¸¸ç ´ë°³ °°Àº ¶æÀ¸·Î È¥¿ëµÈ´Ù. ½Å»ý¹°¿¡´Â ¡°¾ç¼º(benign)¡±°ú ¡°¾Ç¼º(malignant)¡±ÀÌ ÀÖ´Ù. ÀÌ µÑÀÇ ±¸º°Àº ¿©·¯ °¡Áö ±âÁØ¿¡ µû¸£Áö¸¸, ¶§·Î´Â ±¸º°ÀÌ ¾î·Á¿ï ¶§µµ ÀÖ´Ù. ´ë°³ ¾ç¼ºÀº »ý¸í´ÜÃàÀ» Àß ÀÏÀ¸Å°Áö ¾Ê´Â °ÍÀ¸·Î Ä¡·áÈÄ¿¡ Àç¹ßµµ Àß ÇÏÁö ¾Ê´Â´Ù. ÀÌ¿¡ ºñÇØ ¾Ç¼ºÀº Àç¹ß»Ó¸¸ ¾Æ´Ï¶ó ´Ù¸¥ ±â°üÀ¸·Î ¿Å°Ü°¡¼ °°Àº º´º¯ÀÌ ¹ß»ýÇÏ´Â ¡°ÀüÀÌ(metastasis)¡±Çö»óµµ ÀϾÙ. µû¶ó¼ »ý¸íÀ» ´ÜÃà½ÃŰ´Â °æ¿ì°¡ ¸¹À¸¸ç, ´ë°³ Ä¡·á°¡ ¾î·Æ´Ù. |
||
| ¿µ¹® | Dilatation and Curettage(D & C) | ÇÑ±Û | Àڱñܾ¼ú, ÀڱøñÈ®Àå |
|---|---|---|---|
| ¼³¸í | ÀÚ±ÃÀ̶õ žư¡ ¼öÅÂµÇ¾î¼ ºÐ¸¸Àü±îÁö ¹ßÀ°ÇÏ°í ¼ºÀåÇÏ´Â °ø°£ÀÌ´Ù. Àڱüӿ¡ º´º¯ÀÌ ÀÖ¾î ÀÓ½ÅÀÌ °è¼ÓµÉ ¼ö ¾ø°Å³ª ¾Æ´Ï¸é ´Ù¸¥ ÀÌÀ¯·Î ÀӽŵǾî Àִ žƸ¦ Á¦°ÅÇϰíÀÚ ÇÒ °æ¿ì¿¡ »ç¿ëµÇ´Â ¹æ¹ýÀÌ´Ù. ¿©±â¼ ±Ü¾î³»±â À§ÇÏ¿©´Â ¿ì¼± ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇÏ´Â ÀڱøñÀ» È®Àå½ÃÄÑ¾ß ÇÑ´Ù. ¿©±â¿¡´Â ±Þ¼ÓÈ÷ È®ÀåÀ» ½ÃµµÇÏ´Â ¹ý°ú ¼¼È÷ È®ÀåÀ» ½ÃµµÇÏ´Â 2°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ÀڱøñÀ» ±Þ¼ÓÈ÷ È®ÀåÇÒ ¶§´Â Çì°¡¸£ ¸ñ°üÈ®Àå±â(Hegar's dilatator)¸¦ »ç¿ëÇÑ´Ù. À̰ÍÀº ÀÛÀº ±Ý¼Ó¸·´ë·Î ÀÛÀº Å©±âºÎÅÍ Å« Å©±â±îÁö ´Ù¾çÇÑ Å©±â°¡ ÀÖ¾î¼ ¿ì¼± ÀÛÀº ¸·´ë·Î ½ÃÀÛÇÏ¿© Á¡Á¡ Å« Å©±âÀÇ ¸·´ë¸¦ Àڱøñ¿¡ ³Ö¾î¼ ÀڱøñÀ» È®Àå½ÃŲ´Ù. ¼¼È÷ È®Àå½Ãų ¶§´Â Laminaria tent¸¦ ¸ñ°ü¿¡ »ðÀÔÇÏ´Â ¹æ¹ýÀ» »ç¿ëÇÑ´Ù. Laminaria tent¶õ ÇØÃÊ·Î ¸¸µç ÀÛÀº ¸·´ë·Î ¼öºÐÀ» Èí¼öÇϸé Á¡Á¡ ´Ã¾î³ª´Â ¼ºÁúÀÌ ÀÖ´Ù. À̰ÍÀ» ÀÚ±ÃÀÇ ¸ñ¿¡ ³ÖÀ¸¸é À̰ÍÀÌ ¼öºÐÀ» Èí¼öÇÏ¿© ´Ã¾î³ª¹Ç·Î õõÈ÷ ÀÚ±ÃÀÇ ¸ñÀÌ ´Ã¾î³´Ù. ÀڱøñÀÌ ÃæºÐÈ÷ ´Ã¾î³ª¸é ±× ¼ÓÀ¸·Î ³¡ÀÌ ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ ³Ö¾î¼ ÀڱüÓÀÇ º´º¯À̳ª ÀÓ½ÅµÈ Å¾Ƹ¦ ±Ü¾î³»´Âµ¥ ¿©±â¿¡ »ç¿ëµÇ´Â ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ Å¥·¿À̶ó°í ÇÑ´Ù. Ãʱâ ÀÓ½ÅÁßÀý Áï À¯»ê°ú °°Àº ÀӽŰú °ü·ÃµÈ °æ¿ì»Ó¸¸ ¾Æ´Ï¶ó, ºñÀӽŠÀÚ±ÃÀÇ Àڱ󻸷Á¶Á÷ÀÇ Ã¤Ãë ¹× Á¦°Å¸¦ À§Çؼµµ ÇàÇØÁö´Â ¼ö±âÀÌ´Ù. ÀÌ´Â ¿øÄ¢ÀûÀ¸·Î ¸¶ÃëÇÏ¿¡ ½Ç½ÃµÇ´Â °ÍÀ¸·Î Àڱøñ°üÀ» È®ÀåÇÏ°í ±â±¸·Î Àڱà ³»¿ë¹°À» Á¦°ÅÇϰí Å¥·¿À¸·Î Àڱ󻺮À» ±ú²ýÀÌ ÇÑ´Ù. ÀÚ±Ãõ°øÀ̳ª ÀڱøñÀÇ ÆÄ¿ µîÀÇ À§ÇèÀÌ µû¸£¸ç, ¼ö¼úÈÄ °¨¿° ¶Ç´Â ÃâÇ÷ µî¿¡ ´ëÇÑ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù. |
||
| ¿µ¹® | benign | ÇÑ±Û | ¾ç¼º |
|---|---|---|---|
| ¼³¸í | Ä¡À¯°¡ Àß µÇ´Â, Á¾¾çÀÇ °æ¿ì¿¡¼´Â ´Ù¸¥ Á¶Á÷À¸·Î ÆÛÁöÁö ¾Ê°í ±×ºÎºÐ¿¡¼ ¸Ó¹°·¯ ÀÖ´Â Á¾¾çÀ» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | benign tumor | ÇÑ±Û | ¾ç¼ºÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ¹ßÀ°¼Óµµ°¡ ¿Ï¸¸ÇÏ¿© ¼ºÀå¿¡ ÇѰ谡 ÀÖ°í, ÁÖÀ§¿ÍÀÇ °æ°è°¡ ¸íÈ®Çϸç, ´Ù¸¥ Á¶Á÷À¸·Î ÆÛÁöÁö ¾ÊÀ¸¸ç, ħÀ±À̳ª ÀüÀ̸¦ ÀÏÀ¸Å°Áö ¾Æ´ÏÇÏ´Â Á¾¾ç. ¼¶À¯Á¾À̳ª Áö¹æÁ¾ µûÀ§°¡ ÀüÇüÀûÀÎ ¿¹ÀÌ´Ù. ¾ç¼ºÁ¾¾çÀº Á¾¾çÀÌ Á¸ÀçÇÑ´Ù°í ÇØµµ 1Â÷ÀûÀ¸·Î ¼÷ÁÖÀÇ »ý¸íÀ» À§ÇùÇÏ´Â ÀÏÀº ¾ø´Ù. ¾ç¼ºÁ¾¾çÀÇ ¹ßÀ°Çü½ÄÀº ÁÖÀ§ÀÇ Á¶Á÷°£¿¡ ¿Õ·¡ÇÏ´Â ÀÏÀÌ ¾øÀÌ ÁÖÀ§ÀÇ Á¶Á÷À» ¹Ð¾î³»¸ç Áõ½ÄÇÑ´Ù. ¹ßÀ°¼Óµµ´Â ¿Ï¸¸Çϸç ÀüÀÌÇϰųª ÀýÁ¦ ÈÄ Àç¹ßÇÏ´Â ÀÏÀÌ ±ØÈ÷ µå¹°´Ù. Á¾¾ç¼ººÐÀº º¯ÀÌüÀ̱ä ÇÏÁö¸¸ ¼º¼÷ÇÑ Á¤»ó¼¼Æ÷¿Í °ÅÀÇ ´Ù¸¥ °ÍÀÌ ¾ø´Ù. Àü½Å¿¡ ´ëÇÑ ¿µÇâÀº ¾Ç¼ºÁ¾¾çÀÇ °æ¿ì ¾î´À Á¤µµ ¹ßÀ°ÇßÀ» ¶§ Àü½ÅÀÇ ¿µ¾ç»óŰ¡ ¼Õ»óµÇ¾î Ä«Äʽþư¡ µÇÁö¸¸ ¾ç¼ºÁ¾¾çÀÇ °æ¿ì ÀÌ·± ÀÏÀº °ÅÀÇ ¾ø´Ù. ¾ç¼ºÁ¾¾ç°ú ¾Ç¼ºÁ¾¾çÀÇ ¼º»óÀÇ Â÷ÀÌ¿¡ ¾ö¹ÐÇÑ °æ°è´Â ¾ø°í, °æ°è°æº¯À¸·Î º¸ÀÌ´Â Á¾¾çµµ ÀÖ´Ù. |
||
| ¿µ¹® | Benign Prostatic Hyperplasia(BPH) | ÇÑ±Û | Àü¸³»ùºñ´ë |
|---|---|---|---|
| ¼³¸í | 50¼¼ ÀÌ»óÀÇ ³²¼º¿¡ ºó¹ßÇÏ´Â º´À¸·Î Àü¸³»ùÀÇ ¿äµµ ÁÖÀ§ ¿µ¿ª¿¡ Å«°áÀýÀ» Çü¼ºÇÏ¿©, À̰ÍÀÌ Ä¿Áö¸é ¿äµµ¸¦ ¾Ð¹ÚÇÏ¿© ºÎºÐÀû ȤÀº ¿ÏÀüÇÑ ¿äµµÆó»öÀ» ÀÏÀ¸Å°´Â º´ÀÌ´Ù. Áõ»óÀº ¿äµµÆó»ö¿¡ µû¸¥ ¼Òº¯ÀÇ °¨¼Ò¿Í ¹æ±¤ÀÚ±ØÁõ»óÀ¸·Î ºó´¢, ÀÜ´¢°¨, ¼Òº¯À» ÂüÀ» ¼ö ¾ø´Â Áõ»ó µîÀÌ´Ù. Ä¡·á´Â °æ¿äµµ Àü¸³»ù ÀûÃâ¼ú·Î Àü¸³¼±ÀÇ ºñ´ëÇÑ ºÎºÐÀ» ÀýÁ¦ÇØ¾ß ÇÑ´Ù. |
||
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
|---|---|
| PBN | paralytic brachial neuritis; peripheral benign neoplasm; polymyxin B sulfate, bacitracin, and neomyc... |
| CBN | cannabinol; central benign neoplasm; Commission on Biological Nomenclature |
| BPV | benign paroxysmal vertigo; benign positional vertigo; bioprosthetic valve; bovine papilloma virus |
| ad | add [Lat. adde] let there be added [up to a specified amount] [Lat. addetur]; axiodistal; right ear ... |
| SMN | Second Malignant Neoplasm |
|---|---|
| AOD | and other drug |
| EDNOS | Eating Disorder Not Otherwise Specified |
| NOS | Not Otherwise Specified |
| PDD-NOS | Pervasive Developmental Disorder Not Otherwise Specified |
| other-directed | Pertaining to a person readily influenced by the attitudes of others. (05 Mar 2000) |
|---|---|
| transferases (other substituted phosphate groups) | <enzyme> A class of enzymes that transfers substituted phosphate groups. Registry number: EC 2.7.8 (12 Dec 1998) |
| attachment sites | <microbiology, molecular biology> Particular loci in both bacterial and phage DNA molecules at which phage DNA is integrated into the bacterial DNA by recombination between these sites. (12 Dec 1998) |
| binding sites | The reactive parts of a macromolecule that directly participate in its specific combination with another molecule. (12 Dec 1998) |
| binding sites, antibody | Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin. (12 Dec 1998) |
| chromosome fragile sites | Heritable sensitive regions of chromosomes which show up in vitro as non-staining bands. They are associated with chromosome breakage and other aberrations, and, when located on sex chromosomes, they produce phenotypic abnormalities. No abnormal phenotype has been definitely identified with autosomal fragile sites, but some rare autosomal recessive disorders may be due to homozygosity for fragile sites. Fragile sites are designated by the letters "fra" followed by the designation for the specific chromosome and locus. (12 Dec 1998) |
| contact sites A | Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling. (18 Nov 1997) |
| contact sites B | Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling. (18 Nov 1997) |
| crohn disease: sites | <radiology> Oesophagus: rare, stomach (2-20%): granulomatous gastritis, pseudo-post Bilroth-I appearance, ramshorn sign, antral-duodenal fistula, duodenum (4-10%): almost always associated with gastric involvement, bulb and proximal half of duodenum, small bowel (80%): regional enteritis, terminal ileum (alone/in combination): 95%, jejunum/ileum: 15%, commonly associated with medial caecal defect, colon (22-55%): granulomatous colitis, particularly on the right side, transverse stripe sign: contrast within coarse mucosal folds, rectum (35-50%) see: Crohn disease (12 Dec 1998) |
| sequence tagged sites | Short, tagged tracts of DNA sequence that are used as landmarks in genome mapping. In most instances, 200 to 500 base pairs of sequence define a sequence tagged site (sts) that is operationally unique in the human genome (i.e., can be specifically detected by the polymerase chain reaction in the presence of all other genomic sequences). The overwhelming advantage of stss over mapping landmarks defined in other ways is that the means of testing for the presence of a particular sts can be completely described as information in a database. (12 Dec 1998) |
| sequence-tagged sites | Short stretches of DNA sequences that can be detected by use of the polymerase chain reaction. (05 Mar 2000) |
| immunologically privileged sites | Sites where allografts are not readily rejected, probably because these particular areas have poor lymphatic drainage. (05 Mar 2000) |
| antibodies, neoplasm | Immunoglobulins induced by antigens specific for tumours other than the normally occurring histocompatibility antigens. (12 Dec 1998) |
| antigens, neoplasm | Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumour cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. (12 Dec 1998) |
| brain neoplasm | Neoplasms of the part of the central nervous system contained within the cranium. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|